戻る Agenda
New Approaches, Novel Endpoints, and Next-Generation Trials
Session Chair(s)
Jennifer Goldsack, MA, MBA, MS
Chief Executive Officer
Digital Medicine Society (DiMe), United States
Using a case study, we will illustrate CTTI recommended practices for selecting, developing, and including technology-derived endpoints in regulatory trials. Participants can apply best practices learned to other scenarios, including their own work.
Learning Objective : Describe approaches to identifying mobile technology-derived outcome measures that are most valuable and warrant development; Review approaches for optimizing the efficiency of technology-derived novel endpoint development; Discuss how to include and position technology-derived novel endpoints to be most impactful.
Speaker(s)
Facilitator
Jessie Bakker, PHD, MS
Digital Medicine Society (DiMe), United States
Vice President of Digital Measures and Diagnostics
Facilitator
Daniel Rollings Karlin, DrMed, MA, FAPA
MindMed, United States
Chief Medical Officer
Facilitator
Komathi Stem, MS
Glooko, United States
Chief Operating Officer